PPARD and obesity due to melanocortin 4 receptor deficiency: Thus PPARβ/δ has rapidly emerged as apotential target in the battle against dyslipidemia, insulin resistance, type 2diabetes, and obesity with therapeutic efficacy in the treatment ofcardiovascular disease risk factors [39].